Considering that H3.3K27me3 loss is the main molecular feature of both the H3.3K27M mutant and diffuse midline EGFR mutant gliomas, it has been proposed that these tumors be grouped under the denomination of H3.3K27-altered pHGGs [36,38]. This evidence concerns the gene EGFR and central nervous system cancer.